Therapy Areas: Oncology
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
3 April 2025 - Chinese biopharmaceutical company Mabwell (SH:688062) announced on Wednesday that China's National Medical Products Administration (NMPA) has approved the company's novel B7-H...
Quest Diagnostics expands HPV self-collection screening option
2 April 2025 - Diagnostic information services provider Quest Diagnostics (NYSE: DGX) has introduced a human papillomavirus (HPV) self-collection solution for cervical cancer screening, allowing physi...
GenomOncology collaborates with Chronetyx Laboratories for comprehensive genomic profiling in cancer care
1 April 2025 - Precision medicine software company GenomOncology on Monday announced a collaboration with Chronetyx Laboratories, a provider of advanced diagnostic solutions, to accelerate cancer care...
Hoth Therapeutics looks to expand HT-001 US patent coverage
1 April 2025 - Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced on Monday that it has received an official Filing Receipt from the United States Patent and Tradem...
AstraZeneca's Imfinzi wins FDA approval as first perioperative immunotherapy for muscle-invasive bladder cancer
31 March 2025 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has secured US Food and Drug Administration (FDA) approval for Imfinzi (durvalumab...
GE HealthCare acquires full ownership of Nihon Medi-Physics to expand radiopharmaceutical capabilities
31 March 2025 - Medical technology company GE HealthCare (Nasdaq:GEHC) confirmed on Monday that it has completed its acquisition of Sumitomo Chemical's 50% stake in Nihon Medi-Physics Co Ltd (NMP...